C-Path and Replica Analytics Collaboration Aims to Accelerate Rare Disease Research
Critical Path Institute (C-Path) and Replica Analytics, an Aetion company, have announced a partnership that uses synthetic data to help researchers more easily develop drugs to treat rare diseases. Replica Analytics will help generate synthetic datasets across rare and orphan indications in which patient-level datasets are often quite small, which heightens considerations regarding data privacy and accessibility. Together with real data, these synthetic data will help maximize the utility of C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), which provides a standardized and centralized infrastructure to...